Clinical trial
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced…
NCT00242749 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00242749 |
|---|---|
| Title | IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma |
| Official title | A Phase 2 Trial to Evaluate ZD1839 (IRESSA) in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma (Unresectable &Inoperable) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer of Head and Neck |
| Intervention type | Drug |
| Interventions | Gefitinib, Cisplatin and Radiotherapy |
| Enrollment | 47 |
| Start date | Dec 1, 2002 |
| Completion | Jul 1, 2007 |
| First posted | Oct 21, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: